FM
Freire Maria C
Director
BoardF
Insider track record
Board DirectorAcross 13 buy signals with a settled T+90 return. Return basis: close on the day after publication.
Discover the detailed record of transactions filed by Freire Maria C, Director. Officer active across 4 companies, notably Exelixis, INC.. Cumulatively, 24 reports have been recorded. Split: 0 buy · 4 sells. Total volume traded: €909k. History available since 11 May 2021. The latest transaction was disclosed on 27 May 2026 (Attribution). Regulator: SEC (Form 4). All data is free.
Declarations24 total
8,367 shares0Common StockSEC:0000939767-26-000079:0
3,493 shares0Common StockSEC:0001547999-26-000002:0
9,812 shares0Common StockSEC:0000939767-25-000089:0
15,874 shares@ US$20.5036.6% of flowCommon StockSEC:0000939767-25-000022:0
2,032 shares0Common StockSEC:0001035443-25-000048:0
8,250 shares@ US$26.5623.4% of flowCommon StockSEC:0000939767-24-000130:0
1,340 shares0Common StockSEC:0001127602-24-019234:0
18,838 shares0Common StockSEC:0000939767-24-000100:0
1,585 shares0Common StockSEC:0001035443-24-000060:0
960 shares0Common StockSEC:0001127602-23-019542:0
20,718 shares0Common StockSEC:0000939767-23-000060:0
1,125 shares0Common StockSEC:0001035443-23-000080:0
2,311 shares@ US$163.04100.0% of flowCommon StockSEC:0001035443-22-000234:0
1,370 shares0Common StockSEC:0001127602-22-017779:0
19,575 shares0Common StockSEC:0000939767-22-000072:0
738 shares0Common StockSEC:0001035443-22-000029:0
738 shares0Common StockSEC:0001035443-22-000029
775 shares0Common StockSEC:0001127602-21-021337
775 shares0Common StockSEC:0001127602-21-021337:0
8,299 shares0Common StockSEC:0000939767-21-000062:0
8,299 shares0Common StockSEC:0000939767-21-000062
8,275 shares@ US$25.0150.0% of flowCommon StockSEC:0000939767-21-000054
8,275 shares@ US$25.010.0015% mcap50.0% of flowCommon StockSEC:0000939767-21-000054:0
1,373 sharesCommon StockSEC:0001035443-16-000121:0
About Freire Maria C
Maria C. Freire is a Board Member of Exelixis, Inc., Biogen Inc., and Alexandria Real Estate Equities, Inc. She contributes to the strategy and governance of these companies, bringing her expertise in the biopharmaceutical field.